SEARCH:   Advanced

Blood, 15 May 2006, Vol. 107, No. 10, pp. 3832-3840. Prepublished online as a Blood First Edition Paper on January 12, 2006; DOI 10.1182/blood-2005-09-3600. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-09-3600v1 107/10/3832    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mounier, N. Articles by Gisselbrecht, C. Search for Related Content PubMed PubMed Citation Articles by Mounier, N. Articles by Gisselbrecht, C. Related Collections Neoplasia Clinical Trials and Observations Related Article in Blood Online Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy Nicolas Mounier, Michele Spina, Jean Gabarre, Martine Raphael, Giuliano Rizzardini, Jean-Baptiste Golfier, Emanuela Vaccher, Antonino Carbone, Bertrand Coiffier, Guido Chichino, Andre Bosly, Umberto Tirelli, Christian Gisselbrecht, for the French-Italian cooperative group From the Groupe d'Etude des Lymphomes de l'Adulte (GELA), Paris, France; and Gruppo Italiano Cooperativo AIDS e Tumori (GICAT), Aviano, Italy. We aimed to compare AIDS risk–adapted intensive chemotherapy in AIDS-related lymphoma (ARL) patients before and after the advent of highly active antiretroviral therapy (HAART). A total of 485 patients aged from 18 to 67 years were randomly assigned to chemotherapy after stratification according to an HIV score based on performance status, prior AIDS, and CD4+ cell counts below 0.10 x 109/L (100/mm3). A total of 218 good-risk patients (HIV score 0) received ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisolone) or CHOP (doxorubicin, cyclophosphamide, vincristine, and prednisolone); 177 intermediate-risk patients (HIV score 1), CHOP or low-dose CHOP (Ld-CHOP); and 90 poor-risk patients (HIV score 2-3), Ld-CHOP or VS (vincristine and steroid). The 5-year overall survival (OS) in the good-risk group was 51% for ACVBP versus 47% for CHOP (P = .85); in the intermediate-risk group, 28% for CHOP versus 24% for Ld-CHOP (P = .19); and in the poor-risk group, 11% for Ld-CHOP versus 3% for VS (P = .14). The time-dependent Cox model demonstrated that the only significant factors for OS were HAART (relative risk [RR] 1.6, P < .001), HIV score (RR 1.7, P < .001), and the International Prognostic Index (IPI) score (RR 1.5, P < .001) but not chemotherapy regimen. Our findings indicate that in ARL patients, HIV score, IPI score, and HAART affect survival but not the intensity of the CHOP-based chemotherapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Simplified prognostic indicators for AIDS-related lymphoma David J. Straus Blood 2006 107: 3819-3820. [Full Text] [PDF] Related Letter in Blood Online: HAART- and AIDS-related lymphomas Jaswinder Singh, Ashok K. Malani, Siddhartha Ganguly, Suman Kambhampati, and Nicolas Mounier Blood 2006 108: 3621-3622. [Full Text] [PDF] This article has been cited by other articles: V. E. Stone, B. C. Bounds, V. V. Muse, and J. A. Ferry Case 29-2009 -- An 81-Year-Old Man with Weight Loss, Odynophagia, and Failure to Thrive N. Engl. J. Med., September 17, 2009; 361(12): 1189 - 1198. [Full Text] [PDF] M. El-Salem, P. N. Raghunath, M. Marzec, X. Liu, M. Kasprzycka, E. Robertson, and M. A. Wasik Activation of mTORC1 Signaling Pathway in AIDS-Related Lymphomas Am. J. Pathol., August 1, 2009; 175(2): 817 - 824. [Abstract] [Full Text] [PDF] W. O. Mwanda, J. Orem, P. Fu, C. Banura, J. Kakembo, C. A. Onyango, A. Ness, S. Reynolds, J. L. Johnson, V. Subbiah, et al. Dose-Modified Oral Chemotherapy in the Treatment of AIDS-Related Non-Hodgkin's Lymphoma in East Africa J. Clin. Oncol., July 20, 2009; 27(21): 3480 - 3488. [Abstract] [Full Text] [PDF] S. Rothschild, M. Dolder, B. Seifert, U. M. Lutolf, and I. F. Ciernik Radiation Therapy for HIV-Associated Diffuse Large Cell Non-Hodgkin Lymphoma J Int Assoc Physicians AIDS Care (Chic Ill), July 1, 2009; 8(4): 239 - 248. [Abstract] [PDF] A. Carbone, E. Cesarman, M. Spina, A. Gloghini, and T. F. Schulz HIV-associated lymphomas and gamma-herpesviruses Blood, February 5, 2009; 113(6): 1213 - 1224. [Abstract] [Full Text] [PDF] J.-S. Kim, S. J. Kim, J.-S. Kim, E. S. Kim, H.-J. Shin, J. S. Chung, Y.-H. Min, M. H. Lee, Y. J. Choi, S.-M. Bang, et al. Report of Aids-related Lymphoma in South Korea Jpn. J. Clin. Oncol., February 8, 2008; (2008) hym168v1. [Abstract] [Full Text] [PDF] J. Stebbing, A. Sanitt, A. Teague, T. Powles, M. Nelson, B. Gazzard, and M. Bower Prognostic Significance of Immune Subset Measurement in Individuals With AIDS-Associated Kaposi's Sarcoma J. Clin. Oncol., June 1, 2007; 25(16): 2230 - 2235. [Abstract] [Full Text] [PDF] Y.-B. Chen, A. Rahemtullah, and E. Hochberg Primary Effusion Lymphoma Oncologist, May 1, 2007; 12(5): 569 - 576. [Abstract] [Full Text] [PDF] J. Singh, A. K. Malani, S. Ganguly, S. Kambhampati, and N. Mounier HAART- and AIDS-related lymphomas. Blood, November 15, 2006; 108(10): 3621 - 3622. [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020